# An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

> **NCT05505916** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 145 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** KVD900 600 mg
- **DRUG:** KVD900 300 mg

## Key facts

- **NCT ID:** NCT05505916
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05505916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05505916, "An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05505916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*